Lupin Limited has moved closer to the United States enzalutamide market with proposed 120 mg and 160 mg tablets that could reduce pill burden. Patent timing, final approval, market access and competition will determine whether that formulation advantage becomes commercially meaningful.
Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.
Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.
Talzenna plus Xtandi improved rPFS in HRR-mutated metastatic prostate cancer. Find out what TALAPRO-3 could change next.
Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.
Alessa's Enolen earns FDA fast track for localized prostate cancer. Find out how this implant could redefine early-stage treatment and challenge current norms.